ArticleWorld journal of surgical oncology2025
Prognostic and clinical implications of CT-morphometric sarcopenia in adult myxofibrosarcoma patients: a longitudinal analysis.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Resection of locally advanced soft tissue sarcomas of the extremities : Surgical strategies to avoid postoperative complications].Chirurgie (Heidelberg, Germany) · 2026Review
- Postoperative loss of skeletal muscle mass and visceral fat predicts survival and morbidity after surgically treated non-metastatic chondrosarcoma: a longitudinal CT morphometric study.World journal of surgical oncology · 2026Article
- AI-derived CT morphometric phenotypes predict survival, functional decline, and surgical morbidity following curative-intent surgical sarcoma resection.Journal of orthopaedic surgery and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyxofibrosarcoma (MFS) is a rare, aggressive soft tissue sarcoma with a high local recurrence rate, mostly affecting elderly patients. Sarcopenia, the progressive loss of skeletal muscle mass, and its CT-related assessment is an emerging prognostic factor in cancer care, yet its role in MFS remains unclear.
methodsWe conducted a retrospective longitudinal study of 55 patients with high-grade MFS who underwent surgical resection and had at least two CT scans between 2010 and 2024 with a mean scan-interval of 13.2 ± 2.1 months. CT-derived morphometric parameters, including skeletal muscle index (SMI), paraspinal muscle index (PSMI), psoas muscle index (PMI), skeletal muscle density (SMD), and visceral adipose tissue (VAT), were measured at the L3 vertebral level. We analyzed changes in body composition over time and their associations with chemotherapy, radiotherapy, tumor recurrence, postoperative complications, survival and functional status.
resultsSMI, PSMI, PMI, and VAT declined significantly during the disease course, while SMD remained stable. Chemotherapy and local tumor recurrence were associated with greater muscle and fat loss, whereas radiotherapy showed no significant impact. A ≥ 15% decrease in SMI was associated with shorter median overall survival (32 vs. 80 months, p = 0.02). Although pre-treatment sarcopenia did not affect survival it was linked to longer hospital stays (p = 0.03) and increased risk for postoperative wound infections (p = 0.01).
conclusionCT-based body composition analysis offers a practical approach for risk stratification in MFS patients. Routine assessment of sarcopenia using existing imaging can help identify those at higher risk for poor survival, extended hospitalization, and wound complications. Incorporating these metrics into preoperative planning may guide early supportive measures, such as nutritional and wound care interventions. Prospective multicenter studies are needed to confirm these findings and assess whether targeted strategies can reduce sarcopenia-related morbidity and improve outcomes in this rare sarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.